Part B: Supplementary Information Sheet (SIS) |
FR Recognition List Number
|
059
|
Date of Entry 12/19/2022
|
FR Recognition Number
|
1-159
|
Standard | |
ISO 18778 Second edition 2022-06 Respiratory equipment - Particular requirements for basic safety and essential performance of infant cardiorespiratory monitors |
|
Scope/AbstractThis document applies to the basic safety and essential performance of an infant cardiorespiratory monitor, as defined in 3.10, hereafter also referred to as ME equipment, in combination with its accessories:
- intended for use in the home healthcare environment;
- intended for use by a lay operator;
- intended to monitor cardiorespiratory parameters in sleeping or resting children under three years of age; and
- intended for transit-operable use.
NOTE An infant cardiorespiratory monitor can also be used in professional health care facilities.
This document is also applicable to those accessories intended by their manufacturer to be connected to the infant cardiorespiratory monitor, where the characteristics of those accessories can affect the basic safety or essential performance of the infant cardiorespiratory monitor.
EXAMPLE probes, cables distributed alarm system |
|
Extent of Recognition
|
Rationale for Recognition
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies. |
|
Public Law, CFR Citation(s) and Procode(s)*
Regulation Number |
Device Name |
Device Class |
Product Code |
§868.2377 |
Monitor, Apnea, Facility Use
|
Class 2
|
FLS
|
§868.2377 |
Monitor, Apnea, Home Use
|
Class 2
|
NPF
|
|
Relevant FDA Guidance and/or Supportive Publications*
Apnea monitors - Class II Special Controls Guidance Document for Industry and FDA, issued July 2002.
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
FDA Technical Contact
|
Standards Development Organization
|
FDA Specialty Task Group (STG)
|
*These are provided as examples and others may be applicable. |